Top

Clinical Drug Investigation

Published in:

01-04-2001 | Clinical Use

Formoterol Monotherapy Compared with Combined Ipratropium Bromide plus Fenoterol in the Treatment of Chronic Obstructive Pulmonary Disease

Authors: Pd Dr Martin Konermann, Rainer Suchantke, Jürgen Mogck, Jens Brauburger, Matthias Bräutigam

Published in: Clinical Drug Investigation | Issue 4/2001

Abstract

Objectives

To compare the efficacy and tolerability of formoterol (12 or 24μg twice daily) alone with combined ipratropium bromide and fenoterol in the treatment of chronic obstructive pulmonary disease (COPD).

Design and Setting

Randomised, parallel-group, open-label study in 10 German centres.

Patients

101 patients with COPD.

Interventions

The patients were randomised to receive either formoterol 12μg twice daily or a combination of ipratropium bromide 20μg plus fenoterol 50μg three times daily for 4 weeks. Dosages could be doubled if required.

Results

Morning pre-dose airway resistance (R_eff) decreased significantly from 0.87 to 0.66 kPa·L⁻¹·s with formoterol and from 0.81 to 0.66 kPa·L⁻¹·s with combined ipratropium bromide and fenoterol (p = ns). The treatment groups were similar with respect to other lung function parameters, daily clinical symptom scores and salbutamol rescue medication. Adverse events occurred in 7/52 (13.5%) of the formoterol and 11/49 (22.4%) of the combination therapy group, and were the reason for study discontinuation in one (1.9%) versus seven (14.3%) patients. The overall discontinuation rate was 5.8% (3/52) with formoterol and 20.4% (10/49) with ipratropium bromide/fenoterol (p = 0.038).

Conclusions

The efficacy of formoterol monotherapy was comparable with that of combined ipratropium bromide and fenoterol in the treatment of COPD. Formoterol had a better adverse event profile and a lower rate of discontinuations resulting from adverse events.

American Thoracic Society. Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–S120

Higgins MW, Thorn T. Incidence, prevalence and mortality: intra- and inter-country differences. In: Hensley MJ, Saunders NA, editors. Clinical epidemiology of chronic obstructive pulmonary disease. New York: Marcel Dekker, 1990; 23–43

Gillissen A, Schmidt EW. Die chronische Bronchitis und ihre Folgen. Versicherungsmedizin 1996; 48: 200–7PubMed

Camilli AE, Burrows B, Knodson RJ, et al. Longitudinal changes in forced expiratory volume in one second in adults: effects of smoking and smoking cessation. Am Rev Respir Dis 1987; 135: 794–9PubMed

Snider GL. Pulmonary disease in alpha-1-antitrypsin deficiency. Am Intern Med 1989; 111: 957–9

Wettengel R, Böhning W, Cegla U. et al. Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem. Med Klin 1995; 90: 3–7

Leuenberger P, Anderhub HP, Brändli O, et al. Management 1997 of chronic obstructive pulmonary disease. Schweiz Med Wochenschr 1997; 127: 766–82PubMed

Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline on FEV1. JAMA 1994; 272: 1497–505PubMedCrossRef

Easton PA, Jadue C, Dhingra S, et al. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315: 735–9PubMedCrossRef

10.

Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: Comparison with ipratropium bromide alone. Chest 1995; 107: 401–5PubMedCrossRef

11.

Petty TL. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411–9CrossRef

12.

Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115: 966–71PubMedCrossRef

13.

Schäfer H, Ewig S, Gillisson A. Therapeutische Optionen im Management der stabilen chronisch obstruktiven Lungenerkrankung (COPD). Dtsch Med Wochenschr 2000; 125: 230–5PubMedCrossRef

14.

Longhini E, Bozzoni M, Matropasqua B, et al. Evaluation of the intensity and duration of the bronchodilatory action of fenoterol —ipratropium bromide in combination compared with terbutaline and placebo in patients with chronic obstructive lung disease. Respiration 1986; 50 Suppl. 2: 169–72PubMedCrossRef

15.

Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000; 30 Suppl. 1: 6–10

16.

Greffhorst APM, Dahl R, Nowak D, et al. Formoterol dry powder improves the quality of life of patients with COPD whereas the effect of ipratropium bromide is similar to placebo. Eur Resp J 2000; 16: Suppl. 31: 51S

17.

Dahl R, Greefhorst AP, Byrne AM, et al. Onset of action of inhaled formoterol compared to ipratropium bromide in patients with COPD. Eur Resp J 2000; 16: Suppl. 31: 52S

18.

Amgott TR, Kristufek P, Levine B., et al. Effect of inhaled formoterol and oral slow-release theophylline on peak expiratory flow and symptoms in patients with COPD. Am J Resp Crit Care Med 2000; 161(3): 582

19.

Greening A. Pharmacotherapy in COPD. Eur Resp Rev 1997; 45(7): 243–8

20.

Tashkin DP. Multiple dose regimens; impact on compliance. Chest 1995; 107: 176S–82SPubMedCrossRef

21.

Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55(2): 303–22PubMedCrossRef

22.

Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with obstructive airways disease. Thorax 1996; 51: 689–93PubMedCrossRef

23.

Gimeno F, Postma DS, van Altena R. Plethysmographic parameters in the assessment of reversibility of airways obstruction in patients with clinical emphysema. Chest 1993; 104: 467–70PubMedCrossRef

24.

VanSnippenburg R, Duurkens VAM, van den Bosch JMM. Which test best measures bronchodilator drug response in patients with loss of lung elasticity? Eur Respir J 1996; 9: Suppl. 23: 310S

Title: Formoterol Monotherapy Compared with Combined Ipratropium Bromide plus Fenoterol in the Treatment of Chronic Obstructive Pulmonary Disease
Authors: Pd Dr Martin Konermann
Rainer Suchantke
Jürgen Mogck
Jens Brauburger
Matthias Bräutigam
Publication date: 01-04-2001
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 4/2001
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200121040-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Formoterol Monotherapy Compared with Combined Ipratropium Bromide plus Fenoterol in the Treatment of Chronic Obstructive Pulmonary Disease

Abstract

Objectives

Design and Setting

Patients

Interventions

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Design and Setting

Patients

Interventions

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2001

Reliable Acid Suppression with Pantoprazole Contrasts with Rapid Development of Tolerance to Ranitidine in Healthy Individuals

Effect of Hormonal Contraceptives on the Pharmacokinetics of Trovafloxacin in Women

Bioequivalence Study of Two Formulations (Sachet and Tablet) of Cefixime after Single Oral Doses of 200mg in Healthy Male Volunteers

Clinical Equivalence of a Salmeterol/Fluticasone Propionate Combination Product (50/500μg) Delivered via a Chlorofluorocarbon-Free Metered-Dose Inhaler with the Diskus™ in Patients with Moderate to Severe Asthma

Multiple Absorption Patterns of Mesalazine from Two Gastroresistant Tablets in Healthy Male Volunteers

Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder